Ubiquitin-based anticancer therapy: Carpet bombing with proteasome inhibitors vs surgical strikes with E1, E2, E3, or DUB inhibitors()

The proteasome inhibitor bortezomib remains the only ubiquitin pathway effector to become a drug (VELCADE®) and has become a successful treatment for hematological malignancies. While producing a global cellular effect, proteasome inhibitors have not triggered the catastrophe articulated initially i...

Descripción completa

Detalles Bibliográficos
Autores principales: Mattern, Michael R., Wu, Jian, Nicholson, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2012
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127515/
https://www.ncbi.nlm.nih.gov/pubmed/22610084
http://dx.doi.org/10.1016/j.bbamcr.2012.05.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127515/
https://www.ncbi.nlm.nih.gov/pubmed/22610084
http://dx.doi.org/10.1016/j.bbamcr.2012.05.005

Ejemplares similares